<DOC>
	<DOCNO>NCT00104923</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fenretinide , work different way stop growth cancer cell , either kill cell stop divide . Giving fenretinide different way may kill cancer cell . PURPOSE : This phase I trial study side effect best dose intravenous fenretinide treat patient refractory relapse hematologic cancer .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Refractory Relapsed Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose intravenous emulsified fenretinide patient refractory relapse hematologic malignancy . - Determine toxic effect drug patient . - Determine pharmacokinetics vivo activity drug patient . - Determine , preliminarily , disease tumor response patient treated drug . OUTLINE : This pilot , dose-escalation , multicenter study . Patients receive emulsify fenretinide IV continuously 5 day . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients achieve complete partial response may continue receive fenretinide discretion study chair . Cohorts 1 patient receive accelerate escalate dos fenretinide 2 patient experience moderate toxicity ( cumulative across dose level ) OR 1 patient experience dose-limiting toxicity ( DLT ) . After completion accelerate dose-escalation portion , standard dose-escalation portion begin . Cohorts 3-6 patient receive escalate dos fenretinide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . At least 6 patient treated MTD . An additional 12 patient treated MTD . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 follow hematologic malignancy : NonHodgkin 's lymphoma ( NHL ) Hodgkin 's lymphoma Multiple myeloma Acute lymphoblastic leukemia Acute myeloid leukemia Chronic hematologic malignancy poor prognosis ( e.g. , fail 3 prior standard therapy ) , include follow : Chronic lymphocytic leukemia Chronic myelogenous leukemia Indolent NHL Myeloproliferative disorder Refractory relapse disease , define 1 following : Resistant standard therapy refractory relapse disease Progressed standard therapy advance disease No effective treatment exist Measurable evaluable disease No active CNS disease Previously treat leptomeningeal disease brain metastasis allow provided evidence remain cancer positronemission tomography , MRI , spinal fluid cytology PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 ( unless due bone marrow involvement disease ) Platelet count ≥ 75,000/mm^3 ( unless due bone marrow involvement disease ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) No coagulation disorder Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient liver metastasis ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No major cardiovascular disease Pulmonary No major respiratory disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception prior study entry , study , least 6 month study participation No uncontrolled systemic infection No uncontrolled hypertriglyceridemia ( i.e. , triglyceride level &gt; 500 mg/dL ) No know HIV positivity No known allergy egg product No know familial hyperlipidemia disorder No previously undiscovered hypertriglyceridemia No poorly control diabetes PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 2 week since prior chemotherapy except hydroxyurea No concurrent hydroxyurea study drug administration No concurrent anticancer chemotherapy Endocrine therapy No concurrent hormoneablative agent No concurrent steroids No concurrent tamoxifen analogue Radiotherapy No prior cranial radiotherapy More 2 week since prior radiotherapy Surgery More 20 day since prior surgery except biopsy Other Recovered prior therapy More 2 week since prior investigational agent No concurrent investigational agent No concurrent antineoplastic therapy No concurrent antioxidants No concurrent herbal alternative therapy No concurrent vitamin supplement ( e.g. , vitamin A , ascorbic acid , vitamin E ) Standard dose multivitamin allow No concurrent medication may act modulators intracellular ceramide level ceramide cytotoxicity , sphingolipid transport , pglycoprotein multidrug resistance protein 1 ( MRP1 ) drug/lipid transporter , include follow : Cyclosporine analogues Verapamil Ketoconazole Chlorpromazine Mifepristone Indomethacin Sulfinpyrazone No concurrent medication may cause pseudotumor cerebri , include follow : Tetracycline Nalidixic acid Nitrofurantoin Phenytoin Sulfonamides Lithium Amiodarone No concurrent medication control hypertriglyceridemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>